Comparative prognostic value of tumor volume in IOIO and IOTKI treatment for metastatic renal cancer
•Tumor size has a higher predictive ability for prognosis in IOIO therapy compared to IOTKI.•Time-dependent AUC analysis shows tumor size consistently predicts PFS and OS in IOIO therapy.•Tumor size outperforms nephrectomy status and IMDC risk classification in IOIO cases.•Tumor size should be a key...
Gespeichert in:
| Veröffentlicht in: | Urologic oncology 2025-01, Vol.43 (1), p.63.e19-63.e27 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 63.e27 |
|---|---|
| container_issue | 1 |
| container_start_page | 63.e19 |
| container_title | Urologic oncology |
| container_volume | 43 |
| creator | Hara, Takuto Ueki, Hideto Okamura, Yasuyoshi Bando, Yukari Suzuki, Kotaro Terakawa, Tomoaki Chiba, Koji Hyodo, Yoji Teishima, Jun Miyake, Hideaki |
| description | •Tumor size has a higher predictive ability for prognosis in IOIO therapy compared to IOTKI.•Time-dependent AUC analysis shows tumor size consistently predicts PFS and OS in IOIO therapy.•Tumor size outperforms nephrectomy status and IMDC risk classification in IOIO cases.•Tumor size should be a key factor in treatment decisions for mRCC, especially in IOIO therapy.
We aimed to investigate the prognostic significance of tumor size in metastatic renal cell carcinoma (mRCC) by comparing the effectiveness of dual immune checkpoint inhibitor (IOIO) and immune checkpoint inhibitor combined with tyrosine kinase inhibitor (IOTKI) therapies.
This retrospective observational study included patients with mRCC diagnosed between October 2014 and February 2024 who received IOIO or IOTKI treatment at Kobe University Hospital and 5 affiliated hospitals. Clinical and imaging data were collected, and target lesions were measured according to RECIST v.1.1 criteria. Time-dependent ROC curve analysis was performed to evaluate the prognostic value of tumor size, nephrectomy status, and IMDC risk criteria for progression-free survival (PFS) and overall survival (OS).
The study included 180 mRCC patients, consisting of 99 receiving IOIO therapy and 81 receiving IOTKI therapy. Time-dependent AUC analysis showed that tumor size had a higher predictive ability for PFS and OS in the IOIO group than the IOTKI group. In multivariate analysis, tumor size was a significant independent prognostic factor for PFS (HR: 1.010, 95% CI: 1.004–1.016, P < 0.001) in the IOIO group. Moreover, the AUC for tumor size was consistently superior in predicting outcomes compared to nephrectomy status and IMDC risk classification in the IOIO group. Kaplan-Meier curves indicated that tumor size effectively stratified PFS in both nephrectomized and non-nephrectomized cases.
Tumor size significantly impacts the prognosis of mRCC patients treated with IOIO therapy, demonstrating greater predictive ability than nephrectomy status and IMDC risk classification. These findings suggest that tumor volume should be considered a critical factor in treatment decision-making for renal cancer, particularly in patients undergoing IOIO therapy. |
| doi_str_mv | 10.1016/j.urolonc.2024.10.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3128748763</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1078143924006951</els_id><sourcerecordid>3128748763</sourcerecordid><originalsourceid>FETCH-LOGICAL-c287t-6974e598f5314625180b9080019942422e38b7cbc347addbfd72cb0716cbed763</originalsourceid><addsrcrecordid>eNqFkE1rGzEQhkVIqJ20P6FFx1zW1deutKdSTD5MDb44Z6GVZoPM7sqVtIb--8rY7TUnDcMz82oehL5SsqKENt8PqzmGIUx2xQgTpbcitL5BS6okr5hom9tSE6kqKni7QPcpHQihQlH6CS14WzNOJVkitw7j0UST_QnwMYb3KaTsLT6ZYQYcepznMUR8CsM8AvYT3uw2O2wmV4r9rw3OEUweYcq4L9gI2aRszgsiTGbA1kwW4md015shwZfr-4Denp_269dqu3vZrH9uK8uUzFXTSgF1q_qaU9GwmirStUSVb7etYIIx4KqTtrNcSONc1zvJbEckbWwHTjb8AT1e9pZDfs-Qsh59sjAMZoIwJ81pyRGqkAWtL6iNIaUIvT5GP5r4R1Oiz4L1QV8F67Pgc7sILnPfrhFzN4L7P_XPaAF-XAAoh548RJ2sh2LB-Qg2axf8BxF_AYQkjuM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3128748763</pqid></control><display><type>article</type><title>Comparative prognostic value of tumor volume in IOIO and IOTKI treatment for metastatic renal cancer</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Hara, Takuto ; Ueki, Hideto ; Okamura, Yasuyoshi ; Bando, Yukari ; Suzuki, Kotaro ; Terakawa, Tomoaki ; Chiba, Koji ; Hyodo, Yoji ; Teishima, Jun ; Miyake, Hideaki</creator><creatorcontrib>Hara, Takuto ; Ueki, Hideto ; Okamura, Yasuyoshi ; Bando, Yukari ; Suzuki, Kotaro ; Terakawa, Tomoaki ; Chiba, Koji ; Hyodo, Yoji ; Teishima, Jun ; Miyake, Hideaki</creatorcontrib><description>•Tumor size has a higher predictive ability for prognosis in IOIO therapy compared to IOTKI.•Time-dependent AUC analysis shows tumor size consistently predicts PFS and OS in IOIO therapy.•Tumor size outperforms nephrectomy status and IMDC risk classification in IOIO cases.•Tumor size should be a key factor in treatment decisions for mRCC, especially in IOIO therapy.
We aimed to investigate the prognostic significance of tumor size in metastatic renal cell carcinoma (mRCC) by comparing the effectiveness of dual immune checkpoint inhibitor (IOIO) and immune checkpoint inhibitor combined with tyrosine kinase inhibitor (IOTKI) therapies.
This retrospective observational study included patients with mRCC diagnosed between October 2014 and February 2024 who received IOIO or IOTKI treatment at Kobe University Hospital and 5 affiliated hospitals. Clinical and imaging data were collected, and target lesions were measured according to RECIST v.1.1 criteria. Time-dependent ROC curve analysis was performed to evaluate the prognostic value of tumor size, nephrectomy status, and IMDC risk criteria for progression-free survival (PFS) and overall survival (OS).
The study included 180 mRCC patients, consisting of 99 receiving IOIO therapy and 81 receiving IOTKI therapy. Time-dependent AUC analysis showed that tumor size had a higher predictive ability for PFS and OS in the IOIO group than the IOTKI group. In multivariate analysis, tumor size was a significant independent prognostic factor for PFS (HR: 1.010, 95% CI: 1.004–1.016, P < 0.001) in the IOIO group. Moreover, the AUC for tumor size was consistently superior in predicting outcomes compared to nephrectomy status and IMDC risk classification in the IOIO group. Kaplan-Meier curves indicated that tumor size effectively stratified PFS in both nephrectomized and non-nephrectomized cases.
Tumor size significantly impacts the prognosis of mRCC patients treated with IOIO therapy, demonstrating greater predictive ability than nephrectomy status and IMDC risk classification. These findings suggest that tumor volume should be considered a critical factor in treatment decision-making for renal cancer, particularly in patients undergoing IOIO therapy.</description><identifier>ISSN: 1078-1439</identifier><identifier>ISSN: 1873-2496</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2024.10.015</identifier><identifier>PMID: 39523170</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - mortality ; Carcinoma, Renal Cell - pathology ; Female ; Humans ; Immune checkpoint inhibitor ; Immune Checkpoint Inhibitors - therapeutic use ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - mortality ; Kidney Neoplasms - pathology ; Male ; Middle Aged ; Prognosis ; Protein Kinase Inhibitors - therapeutic use ; Renal cell carcinoma ; Retrospective Studies ; Tumor Burden ; Tyrosine kinase inhibitor</subject><ispartof>Urologic oncology, 2025-01, Vol.43 (1), p.63.e19-63.e27</ispartof><rights>2024 Elsevier Inc.</rights><rights>Copyright © 2024 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c287t-6974e598f5314625180b9080019942422e38b7cbc347addbfd72cb0716cbed763</cites><orcidid>0000-0003-4524-2815</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.urolonc.2024.10.015$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39523170$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hara, Takuto</creatorcontrib><creatorcontrib>Ueki, Hideto</creatorcontrib><creatorcontrib>Okamura, Yasuyoshi</creatorcontrib><creatorcontrib>Bando, Yukari</creatorcontrib><creatorcontrib>Suzuki, Kotaro</creatorcontrib><creatorcontrib>Terakawa, Tomoaki</creatorcontrib><creatorcontrib>Chiba, Koji</creatorcontrib><creatorcontrib>Hyodo, Yoji</creatorcontrib><creatorcontrib>Teishima, Jun</creatorcontrib><creatorcontrib>Miyake, Hideaki</creatorcontrib><title>Comparative prognostic value of tumor volume in IOIO and IOTKI treatment for metastatic renal cancer</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>•Tumor size has a higher predictive ability for prognosis in IOIO therapy compared to IOTKI.•Time-dependent AUC analysis shows tumor size consistently predicts PFS and OS in IOIO therapy.•Tumor size outperforms nephrectomy status and IMDC risk classification in IOIO cases.•Tumor size should be a key factor in treatment decisions for mRCC, especially in IOIO therapy.
We aimed to investigate the prognostic significance of tumor size in metastatic renal cell carcinoma (mRCC) by comparing the effectiveness of dual immune checkpoint inhibitor (IOIO) and immune checkpoint inhibitor combined with tyrosine kinase inhibitor (IOTKI) therapies.
This retrospective observational study included patients with mRCC diagnosed between October 2014 and February 2024 who received IOIO or IOTKI treatment at Kobe University Hospital and 5 affiliated hospitals. Clinical and imaging data were collected, and target lesions were measured according to RECIST v.1.1 criteria. Time-dependent ROC curve analysis was performed to evaluate the prognostic value of tumor size, nephrectomy status, and IMDC risk criteria for progression-free survival (PFS) and overall survival (OS).
The study included 180 mRCC patients, consisting of 99 receiving IOIO therapy and 81 receiving IOTKI therapy. Time-dependent AUC analysis showed that tumor size had a higher predictive ability for PFS and OS in the IOIO group than the IOTKI group. In multivariate analysis, tumor size was a significant independent prognostic factor for PFS (HR: 1.010, 95% CI: 1.004–1.016, P < 0.001) in the IOIO group. Moreover, the AUC for tumor size was consistently superior in predicting outcomes compared to nephrectomy status and IMDC risk classification in the IOIO group. Kaplan-Meier curves indicated that tumor size effectively stratified PFS in both nephrectomized and non-nephrectomized cases.
Tumor size significantly impacts the prognosis of mRCC patients treated with IOIO therapy, demonstrating greater predictive ability than nephrectomy status and IMDC risk classification. These findings suggest that tumor volume should be considered a critical factor in treatment decision-making for renal cancer, particularly in patients undergoing IOIO therapy.</description><subject>Aged</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Carcinoma, Renal Cell - mortality</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Immune checkpoint inhibitor</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Kidney Neoplasms - mortality</subject><subject>Kidney Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Renal cell carcinoma</subject><subject>Retrospective Studies</subject><subject>Tumor Burden</subject><subject>Tyrosine kinase inhibitor</subject><issn>1078-1439</issn><issn>1873-2496</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1rGzEQhkVIqJ20P6FFx1zW1deutKdSTD5MDb44Z6GVZoPM7sqVtIb--8rY7TUnDcMz82oehL5SsqKENt8PqzmGIUx2xQgTpbcitL5BS6okr5hom9tSE6kqKni7QPcpHQihQlH6CS14WzNOJVkitw7j0UST_QnwMYb3KaTsLT6ZYQYcepznMUR8CsM8AvYT3uw2O2wmV4r9rw3OEUweYcq4L9gI2aRszgsiTGbA1kwW4md015shwZfr-4Denp_269dqu3vZrH9uK8uUzFXTSgF1q_qaU9GwmirStUSVb7etYIIx4KqTtrNcSONc1zvJbEckbWwHTjb8AT1e9pZDfs-Qsh59sjAMZoIwJ81pyRGqkAWtL6iNIaUIvT5GP5r4R1Oiz4L1QV8F67Pgc7sILnPfrhFzN4L7P_XPaAF-XAAoh548RJ2sh2LB-Qg2axf8BxF_AYQkjuM</recordid><startdate>202501</startdate><enddate>202501</enddate><creator>Hara, Takuto</creator><creator>Ueki, Hideto</creator><creator>Okamura, Yasuyoshi</creator><creator>Bando, Yukari</creator><creator>Suzuki, Kotaro</creator><creator>Terakawa, Tomoaki</creator><creator>Chiba, Koji</creator><creator>Hyodo, Yoji</creator><creator>Teishima, Jun</creator><creator>Miyake, Hideaki</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4524-2815</orcidid></search><sort><creationdate>202501</creationdate><title>Comparative prognostic value of tumor volume in IOIO and IOTKI treatment for metastatic renal cancer</title><author>Hara, Takuto ; Ueki, Hideto ; Okamura, Yasuyoshi ; Bando, Yukari ; Suzuki, Kotaro ; Terakawa, Tomoaki ; Chiba, Koji ; Hyodo, Yoji ; Teishima, Jun ; Miyake, Hideaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c287t-6974e598f5314625180b9080019942422e38b7cbc347addbfd72cb0716cbed763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Aged</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Carcinoma, Renal Cell - mortality</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Immune checkpoint inhibitor</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Kidney Neoplasms - mortality</topic><topic>Kidney Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Renal cell carcinoma</topic><topic>Retrospective Studies</topic><topic>Tumor Burden</topic><topic>Tyrosine kinase inhibitor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hara, Takuto</creatorcontrib><creatorcontrib>Ueki, Hideto</creatorcontrib><creatorcontrib>Okamura, Yasuyoshi</creatorcontrib><creatorcontrib>Bando, Yukari</creatorcontrib><creatorcontrib>Suzuki, Kotaro</creatorcontrib><creatorcontrib>Terakawa, Tomoaki</creatorcontrib><creatorcontrib>Chiba, Koji</creatorcontrib><creatorcontrib>Hyodo, Yoji</creatorcontrib><creatorcontrib>Teishima, Jun</creatorcontrib><creatorcontrib>Miyake, Hideaki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hara, Takuto</au><au>Ueki, Hideto</au><au>Okamura, Yasuyoshi</au><au>Bando, Yukari</au><au>Suzuki, Kotaro</au><au>Terakawa, Tomoaki</au><au>Chiba, Koji</au><au>Hyodo, Yoji</au><au>Teishima, Jun</au><au>Miyake, Hideaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative prognostic value of tumor volume in IOIO and IOTKI treatment for metastatic renal cancer</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2025-01</date><risdate>2025</risdate><volume>43</volume><issue>1</issue><spage>63.e19</spage><epage>63.e27</epage><pages>63.e19-63.e27</pages><issn>1078-1439</issn><issn>1873-2496</issn><eissn>1873-2496</eissn><abstract>•Tumor size has a higher predictive ability for prognosis in IOIO therapy compared to IOTKI.•Time-dependent AUC analysis shows tumor size consistently predicts PFS and OS in IOIO therapy.•Tumor size outperforms nephrectomy status and IMDC risk classification in IOIO cases.•Tumor size should be a key factor in treatment decisions for mRCC, especially in IOIO therapy.
We aimed to investigate the prognostic significance of tumor size in metastatic renal cell carcinoma (mRCC) by comparing the effectiveness of dual immune checkpoint inhibitor (IOIO) and immune checkpoint inhibitor combined with tyrosine kinase inhibitor (IOTKI) therapies.
This retrospective observational study included patients with mRCC diagnosed between October 2014 and February 2024 who received IOIO or IOTKI treatment at Kobe University Hospital and 5 affiliated hospitals. Clinical and imaging data were collected, and target lesions were measured according to RECIST v.1.1 criteria. Time-dependent ROC curve analysis was performed to evaluate the prognostic value of tumor size, nephrectomy status, and IMDC risk criteria for progression-free survival (PFS) and overall survival (OS).
The study included 180 mRCC patients, consisting of 99 receiving IOIO therapy and 81 receiving IOTKI therapy. Time-dependent AUC analysis showed that tumor size had a higher predictive ability for PFS and OS in the IOIO group than the IOTKI group. In multivariate analysis, tumor size was a significant independent prognostic factor for PFS (HR: 1.010, 95% CI: 1.004–1.016, P < 0.001) in the IOIO group. Moreover, the AUC for tumor size was consistently superior in predicting outcomes compared to nephrectomy status and IMDC risk classification in the IOIO group. Kaplan-Meier curves indicated that tumor size effectively stratified PFS in both nephrectomized and non-nephrectomized cases.
Tumor size significantly impacts the prognosis of mRCC patients treated with IOIO therapy, demonstrating greater predictive ability than nephrectomy status and IMDC risk classification. These findings suggest that tumor volume should be considered a critical factor in treatment decision-making for renal cancer, particularly in patients undergoing IOIO therapy.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39523170</pmid><doi>10.1016/j.urolonc.2024.10.015</doi><orcidid>https://orcid.org/0000-0003-4524-2815</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1439 |
| ispartof | Urologic oncology, 2025-01, Vol.43 (1), p.63.e19-63.e27 |
| issn | 1078-1439 1873-2496 1873-2496 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3128748763 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Aged Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - pathology Female Humans Immune checkpoint inhibitor Immune Checkpoint Inhibitors - therapeutic use Kidney Neoplasms - drug therapy Kidney Neoplasms - mortality Kidney Neoplasms - pathology Male Middle Aged Prognosis Protein Kinase Inhibitors - therapeutic use Renal cell carcinoma Retrospective Studies Tumor Burden Tyrosine kinase inhibitor |
| title | Comparative prognostic value of tumor volume in IOIO and IOTKI treatment for metastatic renal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T16%3A59%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20prognostic%20value%20of%20tumor%20volume%20in%20IOIO%20and%20IOTKI%20treatment%20for%20metastatic%20renal%20cancer&rft.jtitle=Urologic%20oncology&rft.au=Hara,%20Takuto&rft.date=2025-01&rft.volume=43&rft.issue=1&rft.spage=63.e19&rft.epage=63.e27&rft.pages=63.e19-63.e27&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2024.10.015&rft_dat=%3Cproquest_cross%3E3128748763%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3128748763&rft_id=info:pmid/39523170&rft_els_id=S1078143924006951&rfr_iscdi=true |